Opus Genetics
IRD
30 hedge funds and large institutions have $8.62M invested in Opus Genetics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 12 closing their positions.
54% more capital invested
Capital invested by funds: $5.61M → $8.62M (+$3.02M)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
1.43% more ownership
Funds ownership: 8.51% → 9.94% (+1.4%)
6% more call options, than puts
Call options by funds: $701K | Put options by funds: $664K
17% less funds holding
Funds holding: 36 → 30 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.35M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$246K |
| 3 |
Two Sigma Advisers
New York
|
+$202K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$199K |
| 5 |
Two Sigma Investments
New York
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.74M |
| 2 |
NPF
Norris Perne & French
Grand Rapids,
Michigan
|
-$417K |
| 3 |
Goldman Sachs
New York
|
-$197K |
| 4 |
Renaissance Technologies
New York
|
-$188K |
| 5 |
State Street
Boston,
Massachusetts
|
-$183K |
IRD Hedge Fund Activity: Q3 2021 in Review
30 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2021, worth a combined $8.62M — up 54% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IRD and 6 opened new positions — a net loss of 6 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $4.35M. The largest seller was Marshall Wace, exiting entirely with an estimated $1.74M sold.
- 30 institutional investors held Opus Genetics (IRD) as of Q3 2021, down from 36 in Q2 2021.
- Funds reported $8.62M of Opus Genetics stock for Q3 2021, up 54% quarter-over-quarter.
- 6 funds opened new Opus Genetics positions in Q3 2021 and 12 closed out, a net change of -6 holders.
- The largest Opus Genetics buyer in Q3 2021 was Vanguard Group, an estimated $4.35M added.
- The largest Opus Genetics seller in Q3 2021 was Marshall Wace, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2021.